Edwards Lifesciences Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform
October 28, 2024 8:19 AM EDTBernstein SocGen Group analyst Lee Hambright upgraded Edwards Lifesciences (NYSE: EW) from to Market Perform.
The analyst comments "Our previous Underperform call on EW was based on the view that the TAVR market was experiencing slowing growth and increased competition. Now as... More
BTIG Reiterates Neutral Rating on Edwards Lifesciences (EW)
October 25, 2024 5:22 AM EDTBTIG analyst Marie Thibault reiterated a Neutral rating on Edwards Lifesciences (NYSE: EW).
The analyst comments "There were a few moving parts with this quarter's print following the sale of the Critical Care business in September as well as the discontinuation of a small non-core product group in the Surgical Structural Heart business that generates ~$60-70M in annual sales. Excluding these items, EW grew revenue by 9.6% y/y CC in Q3 and reported adj. EPS of $0.67. Total TAVR sales of $1.023B were $13M above consensus of $1.010B (+6.5% y/y rep., +7.2% CC).... More
